Education
About Us
Working with TipRanks
Follow Us
Camurus AB (SE:CAMX)
:CAMX
CAMX Stock Chart & Stats
kr665.00
-kr17.00(-2.71%)
At close: 4:00 PM EST
kr665.00
-kr17.00(-2.71%)
Day’s Range― - ―
52-Week Rangekr483.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)126.83K
Market Cap
kr41.38B
Enterprise Valuekr36.52B
Total Cash (Recent Filing)kr3.51B
Total Debt (Recent Filing)kr106.31M
Price to Earnings (P/E)52.2
Beta0.66
Next Earnings
Feb 12, 2026EPS Estimate
2.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,880,184
10 Day Avg. Volume148,560
30 Day Avg. Volume126,834
Financial Highlights & Ratios
PEG Ratio-15.28
Price to Book (P/B)9.97
Price to Sales (P/S)17.56
P/FCF Ratio91.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr483.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr41.38B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Feb 12, 2026 which is today.
How were Camurus AB’s earnings last quarter?
Currently, no data Available
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Overvalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 2.37.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,880,184 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with both significant achievements and notable challenges. Camurus showed strong revenue growth, profitability, and positive R&D developments, but faced hurdles with lowered revenue guidance, slowed Buvidal sales, and funding issues in the U.K. market.View all SE:CAMX earnings summariesTechnical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---